Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
65.99
Oct 30 • 3:59 PM ET Dollar change-1.13 Percentage change(-1.68%)
Aftermarket Close
66.00
Aftermarket • 7:55 PM ET Dollar change+0.01 Percentage change(0.02%)
Oct 30, 4:40 PMTransMedics grants inducement equity awards to nine new employees, including CFO Araujo, under Nasdaq Listing Rule 5635(c)(4)
Index
RUT
Market Cap
2.29B
Enterprise Value
2.68B
Income
151.70M
Sales
668.47M
Book/sh
14.96
Cash/sh
13.63
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
898
IPO
May 02, 2019
P/E
17.17
Forward P/E
29.19
PEG
-
P/S
3.42
P/B
4.41
P/C
4.84
P/FCF
28.95
EV/EBITDA
22.73
EV/Sales
4.01
Quick Ratio
6.07
Current Ratio
6.62
Debt/Eq
1.67
LT Debt/Eq
1.63
Option/Short
Yes / Yes
EPS (ttm)
3.84
EPS next Y
2.26
EPS next Q
0.30
EPS this Y
-69.91%
EPS next Y
54.25%
EPS next 5Y
-13.19%
EPS past 3/5Y
- -
Sales past 3/5Y
86.42% 88.21%
EPS Y/Y TTM
108.84%
Sales Y/Y TTM
25.82%
EPS Q/Q
-55.84%
Sales Q/Q
20.70%
Insider Own
3.86%
Insider Trans
-0.62%
Inst Own
105.36%
Inst Trans
-5.02%
ROA
12.88%
ROE
36.28%
ROIC
11.14%
Gross Margin
57.75%
Oper. Margin
12.21%
Profit Margin
22.69%
SMA20
-11.02%
SMA50
-19.18%
SMA200
-30.16%
Trades
Shs Outstand
34.63M
Shs Float
33.34M
52W High
156.00 -57.70%
52W Low
60.10 9.79%
Volatility
4.14% 4.97%
ATR (14)
3.64
RSI (14)
28.92
Beta
2.09
Rel Volume
1.08
Avg Volume
832.64K
Volume
900,114
Perf Week
-6.71%
Perf Month
-16.09%
Perf Quarter
-19.08%
Perf Half Y
-34.02%
Perf YTD
-45.75%
Perf Year
-51.40%
Perf 3Y
79.61%
Perf 5Y
140.58%
Perf 10Y
-
Prev Close
67.12
Price
65.99
Change %
-1.68%
Consensus
Buy
Avg. Price Target
$98.73
Implied Upside
+49.6%
Analysts12incl. previous ratings
Rating Distribution8 Buy · 4 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Oct 07, 2026Initiated
BCS logoBBarclays
Overweight$120+81.8%
Jul 28, 2026Initiated
UBS logoUUBS
Neutral$80+21.2%
May 06, 2026Downgrade
OPY logoOOppenheimer
Outperform → Perform
Oct 23, 2025Upgrade
NNeedham
Hold → Buy$148+124.3%
Oct 13, 2025Initiated
JEF logoJJefferies
Buy$145+119.7%
Sep 16, 2025Initiated
EVR logoEEvercore ISI
Outperform$155+134.9%
Sep 04, 2025Initiated
SF logoSStifel
Hold$115+74.3%
Dec 17, 2024Downgrade
JPM logoJJP Morgan
Overweight → Neutral$116 → $75+13.7%
Nov 22, 2024Downgrade
NNeedham
Buy → Hold
Oct 29, 2024Reiterated
OPY logoOOppenheimer
Outperform$200 → $125+89.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Weill DavidDirectorSep 11 '26Buy81.631,336109,05816,392Sep 14 04:30 PM
Gunderson Thomas J.DirectorJun 15 '26Option Exercise2.2119,28542,62026,266Jun 17 04:15 PM
Gunderson Thomas J.DirectorJun 15 '26Sale75.069,624722,37716,642Jun 17 04:15 PM
THOMAS GUNDERSONDirectorJun 15 '26Proposed Sale75.069,624722,403Jun 15 06:06 PM
Lovell StephanieDirectorMar 04 '26Sale149.621,193178,4972,866Mar 06 06:12 PM
Weill DavidDirectorMar 04 '26Option Exercise14.203,57150,70815,705Mar 06 06:09 PM
Weill DavidDirectorMar 04 '26Sale146.823,571524,29412,134Mar 06 06:09 PM
Hernandez GerardoChief Financial OfficerMar 04 '26Option Exercise71.177,236515,00120,601Mar 04 09:40 PM
Hernandez GerardoChief Financial OfficerMar 04 '26Sale147.217,2361,065,21214,689Mar 04 09:40 PM
Hernandez GerardoChief Financial OfficerMar 02 '26Sale139.1237552,17014,689Mar 04 09:40 PM
Ranganath Anil P.See remarksMar 02 '26Sale139.12864120,20013,091Mar 04 08:40 PM
Corcoran NicholasSee remarksMar 02 '26Sale139.122,966412,63029,831Mar 04 08:40 PM
GERARDO P HERNANDEZ OfficerMar 04 '26Proposed Sale147.217,2361,065,183Mar 04 04:34 PM
STEPHANIE LOVELLDirectorMar 04 '26Proposed Sale149.621,193178,491Mar 04 04:23 PM
DAVID WEILLDirectorMar 04 '26Proposed Sale146.823,571524,295Mar 04 04:18 PM
Weill DavidDirectorDec 03 '25Option Exercise14.205,00071,00017,134Dec 05 04:30 PM
Weill DavidDirectorDec 03 '25Sale138.645,000693,20012,134Dec 05 04:30 PM
Hernandez GerardoChief Financial OfficerDec 04 '25Sale139.62920128,45015,064Dec 05 04:30 PM
DAVID WEILLDirectorDec 03 '25Proposed Sale138.645,000693,210Dec 03 04:06 PM
Ranganath Anil P.See remarksNov 25 '25Option Exercise93.883,000281,64016,955Nov 26 04:30 PM
Ranganath Anil P.See remarksNov 25 '25Sale145.223,000435,66013,955Nov 26 04:30 PM
ANIL P RANGANATHOfficerNov 25 '25Proposed Sale145.223,000435,674Nov 25 04:11 PM
Hassanein Waleed HPresident & CEONov 17 '25Buy114.008,7751,000,350495,009Nov 18 04:30 PM
TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.
FounderDr. Waleed H. Hassanein M.D.
Senior Vice President of Supply Chain & OperationsMr. Nicholas Corcoran
Senior Vice President of InternationalDr. Tamer I. Khayal M.D.
Chief Financial Officer & TreasurerMr. Fernando Araujo
Senior VPMr. Matthew Forsyth